| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/29/2004 | WO2004035026A1 Deferacirox dispersible tablets |
| 04/29/2004 | WO2004035021A2 Buccal polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
| 04/29/2004 | WO2004035020A2 Controlled release preparation |
| 04/29/2004 | WO2004035006A2 Methods and compositions for immunization against hiv |
| 04/29/2004 | WO2004035005A2 Three layer tear formulation |
| 04/29/2004 | WO2004035004A2 Effervescent compositions comprising bisphosphonates and methods related thereto |
| 04/29/2004 | WO2004035002A2 Benzopyranone compounds, compositions thereof, and methods for treating or preventing cancer |
| 04/29/2004 | WO2004035001A2 Calcium channel agonists for psychotherapeutic use |
| 04/29/2004 | WO2004035000A2 Enhancement of sleep with t-type calcium channel antagonists |
| 04/29/2004 | WO2004034999A2 Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| 04/29/2004 | WO2004034996A2 TREATING ALCOHOL AND OR SUBSTANCE ABUSE BY ANTAGONIZING α 2 ADRENERGIC RECEPTORS WITH WEAK DOPAMINE BLOCKING |
| 04/29/2004 | WO2004034993A2 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |
| 04/29/2004 | WO2004034992A2 Encapsulation and deaggregation of polyene antibiotics using poly(ethylene glycol)-phospholipid micelles |
| 04/29/2004 | WO2004034990A2 Methods and compositions for use in treating cancer |
| 04/29/2004 | WO2004034987A2 Treatment for reactive arthritis or bursitis |
| 04/29/2004 | WO2004034985A2 Chemical compounds |
| 04/29/2004 | WO2004034983A2 Preparation of triazospiro compounds |
| 04/29/2004 | WO2004034980A2 Treatment for traumatic synovitis and damaged articular cartilage |
| 04/29/2004 | WO2004034978A2 Treating obesity with selective androgen receptor modulators |
| 04/29/2004 | WO2004034977A2 Orally administered peptides synergize statin activity |
| 04/29/2004 | WO2004034976A2 Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer nd anti-infective agents |
| 04/29/2004 | WO2004034975A2 Sustained release profile modification |
| 04/29/2004 | WO2004034973A2 Method of treating snoring and other obstructive breathing disorders |
| 04/29/2004 | WO2004034972A2 Compounds, compositions, and methods |
| 04/29/2004 | WO2004034968A2 Combination therapy for controlling appetites |
| 04/29/2004 | WO2004034965A2 Method for treating cancer |
| 04/29/2004 | WO2004034963A2 Methods and compositions using cholinesterase inhibitors |
| 04/29/2004 | WO2004034962A2 Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
| 04/29/2004 | WO2004034959A2 Multiparticulate modified release composition comprising beraprost |
| 04/29/2004 | WO2004034957A2 Methods for treatment of helicobacter pylori-associated disorders |
| 04/29/2004 | WO2004034889A2 Photodynamic therapy for ocular neovascularization |
| 04/29/2004 | WO2004034787A1 Method of orally treating inflammatory skin conditions with prodrugs of 5-fluorouracil |
| 04/29/2004 | WO2004028677A3 Perfluorocarbon emulsions with non-fluorinated surfactants |
| 04/29/2004 | WO2004026303A3 Use of posaconazole for the treatment of fungal infections |
| 04/29/2004 | WO2004024085A3 Use of pde iv inhibitors to treat angiogenesis |
| 04/29/2004 | WO2004022782A3 Compositions and methods for tissue specific or inducible inhibition of gene expression |
| 04/29/2004 | WO2004022040A3 Treatment of metastatic breast cancer with anthracyclines, taxanes and an histamine antagonist |
| 04/29/2004 | WO2004020979A9 Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade |
| 04/29/2004 | WO2004019999A3 Agent delivery particle |
| 04/29/2004 | WO2004019868A3 N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| 04/29/2004 | WO2004018472A3 Pyrimido compounds having antiproliferative activity |
| 04/29/2004 | WO2004017949A3 Prophylaxis and treatment of infectious diseases |
| 04/29/2004 | WO2004017940A3 Pharmaceutically active lipid based formulation of sn38 |
| 04/29/2004 | WO2004017914A3 Inhalation composition |
| 04/29/2004 | WO2004016277A3 Extraction of pharmaceutically active cannabinoids from plant materials |
| 04/29/2004 | WO2004016221A3 Sulfonamides as potassium channel blockers |
| 04/29/2004 | WO2004016101A3 Compositions comprising dietary fat complexer and methods for their use |
| 04/29/2004 | WO2004016086A3 2,4,5-trisubstituted imidazoles and their use as anti-microbial agents |
| 04/29/2004 | WO2004015107A3 Further novel forms of interfering rna molecules |
| 04/29/2004 | WO2004012732A3 Use of a proteasome inhibitor in the treatment of endothelial dysfunction and/or in a low-dose proteasome inhibitor therapy |
| 04/29/2004 | WO2004012652A3 Treatment of multiple sclerosis with brain targeted anti oxidant compounds |
| 04/29/2004 | WO2004012506A3 Antimicrobial compounds |
| 04/29/2004 | WO2004011402A3 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 04/29/2004 | WO2004007770A3 Method for diagnosis of intestinal-type gastric tumors |
| 04/29/2004 | WO2004006888A3 Stabilization of the profile of release of active substances from a formulation |
| 04/29/2004 | WO2004006858A3 Compounds, compositions, and methods employing same |
| 04/29/2004 | WO2004003185A3 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/29/2004 | WO2004000265A3 Process for the preparation of robust formulations of valacyclovir hydrochloride tablets |
| 04/29/2004 | WO2004000230A3 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders |
| 04/29/2004 | WO2004000016A3 Antimicrobial compositions, products and methods employing same |
| 04/29/2004 | WO2003104282A8 Glycoprotein vi - fc fusion protein for treating vascular disorders |
| 04/29/2004 | WO2003104255A3 Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives as ligands for the neuropeptide y5 receptor |
| 04/29/2004 | WO2003103653A8 Methods of treating alzheimer's disease using aryl alkanoic acid amides |
| 04/29/2004 | WO2003101996A8 Esters in position 20 of camptothecins |
| 04/29/2004 | WO2003101373A3 Thiazolidinedione derivatives in therapeutic and prophylactic methods |
| 04/29/2004 | WO2003099823A3 1,3-diaza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 04/29/2004 | WO2003097649A3 1-oxa-dibenzoazulenes as inhibitors of tumor necrosis factor production and intermediates for the preparation thereof |
| 04/29/2004 | WO2003093242A3 Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade |
| 04/29/2004 | WO2003087408A3 Schizophrenia associated genes |
| 04/29/2004 | WO2003087368A3 Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification |
| 04/29/2004 | WO2003087367A3 Means and methods for the specific inhibition of genes in cells and tissue of the cns and/or eye |
| 04/29/2004 | WO2003086303A3 Farnesoid x-activated receptor agonists |
| 04/29/2004 | WO2003086282A3 Nitric oxide donors, compositions and methods of use |
| 04/29/2004 | WO2003086267B1 Multi-phase, multi-compartment capsular system |
| 04/29/2004 | WO2003082798A8 Natural compounds and derivatives thereof for the prevention and treatment of cardiovascular, hepatic and renal diseases and for cosmetic applications |
| 04/29/2004 | WO2003057223A9 Method of treating sexual dysfunctions with delta opioid receptor agonist compounds |
| 04/29/2004 | WO2003057134A3 Specific binding agents of human angiopoietin-2 |
| 04/29/2004 | WO2003055500A8 Pharmaceutical compositions for the treatment or prevention of osteoporosis |
| 04/29/2004 | WO2003053473A3 Ph-sensitive polymeric conjugates of an anthracycline drug |
| 04/29/2004 | WO2003028667A9 Semisolid topical hormonal compositions and methods for treatment |
| 04/29/2004 | WO2003028459A8 Nicotinic acid-heterocyclyl-amides and analogous pyrimidine derivatives serving as pesticides |
| 04/29/2004 | WO2003020949A3 Targeted nucleic acid constructs and uses related thereto |
| 04/29/2004 | WO2003013537A9 Irinotecan for treatment of cancer |
| 04/29/2004 | WO2003013536A9 Methods for treatment of cancer using irinotecan based on ugt1a1 |
| 04/29/2004 | WO2003013535A9 Use of irinotecan for improved treatment of cancer based on mdr1 |
| 04/29/2004 | WO2003013534A9 Methods for the treatment of cancer with irinotecan based on cyp3a5 |
| 04/29/2004 | WO2003013533A9 Methods for improved treatment of cancer with irinotecan based on mrp1 |
| 04/29/2004 | WO2003009807A3 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 04/29/2004 | WO2003007934A8 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 04/29/2004 | WO2003003972A3 Kinetic resolution of a intermediate useful in the production of benazepril and analogues thereof |
| 04/29/2004 | WO2003003006A3 New potent, selective and non toxic c-kit inhibitors |
| 04/29/2004 | WO2003003004A3 Method for identifying compounds the specifically deplete mast cells |
| 04/29/2004 | WO2002102787A3 Novel sulfonic acid derivatives |
| 04/29/2004 | WO2002102391A3 Composition comprising nanoparticulate spironolactone |
| 04/29/2004 | WO2002100417A8 Use of glycosaminoglycans for the treatment of hiv-associated nephropathy |
| 04/29/2004 | WO2002079169A8 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 04/29/2004 | WO2002078626A3 Therapeutic combinations for cardiovascular and inflammatory indications |
| 04/29/2004 | WO2002066009A8 Modulated release particles for aerosol delivery |
| 04/29/2004 | WO2002064134A8 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies |
| 04/29/2004 | WO2002055089A9 Immunoassay technique using multispecific molecules |